In medicine, nanotechnology has sparked a rapidly growing interest as it promises to solve a number of issues associated with conventional therapeutic agents, including their poor water solubility (at least, for most anticancer drugs), lack of targeting capability, nonspecific distribution, systemic toxicity, and low therapeutic index. Over the past several decades, remarkable progress has been made in the development and application of engineered nanoparticles to treat cancer more effectively. For example, therapeutic agents have been integrated with nanoparticles engineered with optimal sizes, shapes, and surface properties to increase their solubility, prolong their circulation half-life, improve their biodistribution, and reduce their immunogenicity. Nanoparticles and their payloads have also been favorably delivered into tumors by taking advantage of the pathophysiological conditions, such as the enhanced permeability and retention effect, and the spatial variations in the pH value. Additionally, targeting ligands (e.g., small organic molecules, peptides, antibodies, and nucleic acids) have been added to the surface of nanoparticles to specifically target cancerous cells through selective binding to the receptors overexpressed on their surface. Furthermore, it has been demonstrated that multiple types of therapeutic drugs and/or diagnostic agents (e.g., contrast agents) could be delivered through the same carrier to enable combination therapy with a potential to overcome multidrug resistance, and real-time readout on the treatment efficacy. It is anticipated that precisely engineered nanoparticles will emerge as the next-generation platform for cancer therapy and many other biomedical applications.

Engineered Nanoparticles for Drug Delivery in Cancer Therapy

Challenges in liver cancer and possible treatment approaches.

Medical diagnosis and therapy are essential for providing patients with proper care, although inefficient diagnosis and therapy are usually associated with either improper detection of the diseases, unsatisfactory therapeutic outcomes and/or serious adverse reactions. Advances in the design of various diagnostic and therapeutic agents, and the recent trend of utilizing molecules for both therapeutic and diagnostic applications (i.e. theranostics), still have not achieved the maximum benefits of controlling the navigation and biodistribution of these molecules within the biological system. The key challenges towards the use of these agents, from small molecules to macromolecular drugs (e.g. natural, proteins and nucleic acids-based drugs, or synthetic, polymer-based conjugates, carriers or other systems), are, for example, the loss of activity via rapid clearance or degradation, inefficient delivery to the target sites, and inappropriate probing of the disease states, dependent on the particular disease and its location in the body. The concept of nanotechnology has been initiated early in 1959 by Richard Feynman in his famous historical talk at Caltech “There’s Plenty of Room at the Bottom”, with introduction of the possibility of manipulating materials at the atomic and molecular levels.1 In 1974, Norio Taniguchi, at Tokyo University, first utilized the term “nanotechnology” referring to the design of materials on the nanoscale.2 In the early 1990’s and until now, the use of nanomaterials of different nature (organic and inorganic), and for various applications (multiple disciplines) has been greatly expanded, in particular, over the last couple of decades.3-4 In the medical field, nanotechnology has emerged to include non-invasive systems for probing of disease and also capable of carrying cargo for localized high concentration delivery, known as “nanomedicine”, with reduction of off-target effects. The use of nanomaterials, in particular polymeric nanostructures, has demonstrated efficiency in improving delivery of diagnostic and therapeutic agents to the target sites, and the feasibility of incorporating several therapeutic/diagnostic/targeting moieties within specific compartments of the nanoparticles, with control of their navigation in the body and to the target sites. Further understanding of the nature and microenvironments of biological systems (e.g. different pH, temperature, permeability, drainage, or overexpressing proteins, enzymes or receptors), and the barriers towards the delivery of various moieties to their destinations, which could be either intra- or extracellular, has aided the design of nanomaterials that could evade the various physiological barriers. Selective delivery to the site of the disease can increase the therapeutic efficacy, imaging contrast and accuracy, reduce adverse reactions, and reduce the dose and cost of medications.

Initially, platform technologies were the target for nanostructure designs, but with the complications of biological systems, it has been recognized over the past decade that disease- and patient-specific medical treatment is needed for efficacy—this review highlights a few examples developed within the past couple of years, with a focus on in vivo studies together with novel designs and significant advances in syntheses. The advantages of polymeric nanostructures over other types of nanomaterials are based upon the flexibility over which their structures can be modified to yield materials of various compositions, morphologies, sizes, surface properties, with possibility of hierarchical assembly of several nanomaterials of various components into one construct that can be accommodated with a variety of therapeutic, diagnostic and/or targeting moieties, within selective compartments of the nanodevices. High efficiency in diagnosis and treatment of diseases and improving patient quality of life and compliance can be achieved through understanding the molecular events associated with various diseases, and combining the advances in the design of therapeutic and diagnostic agents and nanomaterials, together with the innovative instruments utilized for monitoring these agents. This review will focus on several recent advances in the design of polymeric nanoparticles that have been utilized for delivery of diagnostic and/or therapeutic agents, and the various barriers towards the clinical development of these materials. After a brief overview of the capabilities and challenges with medical imaging and therapy, in general, disease-specific examples of polymer nanoparticles designed specifically to overcome the challenges and address unmet medical needs will be discussed in detail.

/pdf/polymeric-nanostructures-for-imaging-and-therapy-3eaomfjdgi.pdf

Polymeric Nanostructures for Imaging and Therapy.

Modulating ROS to overcome multidrug resistance in cancer.

Three-dimensional in vitro tumor models for cancer research and drug evaluation.

Different strategies to overcome multidrug resistance in cancer.

https://cyberleninka.org/article/n/182524.pdf

Recent developments in the co-delivery of siRNA and small molecule anticancer drugs for cancer treatment

The study was aimed at investigating the feasibility of using a poly (amidoamine) (PAMAM) dendrimer as a carrier for topical iontophoretic delivery of an antisense oligonucleotide (ASO). Bcl-2, an anti-apoptotic protein implicated in skin cancer, was used as the model target protein to demonstrate the topical gene silencing approach. Confocal laser scanning microscopy studies demonstrated that the iontophoretically delivered ASO–dendrimer complex can reach the viable epidermis in porcine skin. In contrast, passively delivered free or dendrimer complexed ASO was mainly localized to the stratum corneum. The cell uptake of ASO was significantly enhanced by the dendrimer complex and the complex suppressed Bcl-2 levels in the cell. In the skin cancer mouse model, the iontophoretically delivered ASO–dendrimer complex reduced the tumor volume by 45% and was consistent with the reduction in Bcl-2 protein levels. The iontophoretically delivered ASO–dendrimer complex caused significant apoptosis in skin tumor. Overall, the findings from this study demonstrate that dendrimers are promising nanocarriers for developing topical gene silencing approaches for skin diseases.

Topical gene silencing by iontophoretic delivery of an antisense oligonucleotide–dendrimer nanocomplex: the proof of concept in a skin cancer mouse model

/pdf/multifunctional-drug-nanocarriers-formed-by-crgd-conjugated-5164tbjic5.pdf

Multifunctional drug nanocarriers formed by cRGD-conjugated βCD-PAMAM-PEG for targeted cancer therapy.

Significant efforts have been expended to mitigate plasticizer migration from crosslinked methacrylic and poly(vinyl chloride) polymer networks by synthesizing reactive plasticizers that can blend homogenously within the networks to reduce polymer property change, acute toxicity and downstream environmental effects of plasticizer migration with limited and varying amount of success. We hypothesized that appropriate thiol-functionalized nanogels synthesized using the same monomers as the parent network to generate highly compact, crosslinked structures will form thermally stable, homogenous networks and perform as optimal reactive plasticizers. Nanogels were synthesized via a thiol-Michael addition solution polymerization and incorporated at different mass ratios within a polyethylene glycol 400 urethane dimethacrylic monomer to form photo-crosslinked networks. While maintaining the inherent hydrolytic stability, thermal stability and biocompatibility of the parent matrix at ~99% acrylic group conversion, the PEG400 urethane dimethacrylic -nanogel networks retained optical clarity with >90% visible light transmission at 20wt% nanogel concentration within the matrix. The addition of the nanogels also enhanced the elongation of the parent matrix by up to 320%, while a 37°C reduction in glass transition temperature (∆Tg) and ≥50% reduction in modulus was observed. A 52% reduction in the shrinkage stress of the material was also noted. The results indicate that the application of thiol-functionalized nanogels as plasticizers to alter the bulk properties of the parent matrix while mitigating plasticizer migration by covalently crosslinking the nanogels within the polymer matrix provides a simple yet efficient technique to generate network-specific plasticizers with the ability to alter targeted properties within polymers.

Manju Saraswathy

Papers

Different strategies to overcome multidrug resistance in cancer.

Recent developments in the co-delivery of siRNA and small molecule anticancer drugs for cancer treatment

Topical gene silencing by iontophoretic delivery of an antisense oligonucleotide–dendrimer nanocomplex: the proof of concept in a skin cancer mouse model

Multifunctional drug nanocarriers formed by cRGD-conjugated βCD-PAMAM-PEG for targeted cancer therapy.

Thiol-functionalized nanogels as reactive plasticizers for crosslinked polymer networks